WFDC1 Antibody

What is WFDC1 and why is it significant in research?

WFDC1 (WAP Four-Disulfide Core Domain 1), also known as ps20, is a secreted protein characterized by its WAP-type four-disulfide core domain. This protein has significant research value due to its:

• Role as a modulator of inflammatory and wound repair responses

• Potential tumor suppressor function in multiple cancers

• Involvement in regulating host immune responses to infections

• Regulatory function in tissue homeostasis

WFDC1 is mapped to chromosome 16q24, an area frequently showing loss of heterozygosity in various cancers including prostate, breast, and hepatocellular cancers . The gene encodes a protein that shares 81% amino acid identity with rat ps20 protein, which was originally identified as a secreted growth inhibitor . Due to its location and potential growth inhibitory properties, WFDC1 has been suggested to function as a tumor suppressor gene .

What are the key characteristics of WFDC1 protein structure?

WFDC1 protein contains:

• A WAP signature motif with eight cysteines forming four disulfide bonds at the core

• Functions as a protease inhibitor in many family members

• Calculated molecular weight of approximately 24 kDa (220 amino acids)

• Observed molecular weight in laboratory conditions of 29 kDa

The protein structure includes specific domains that can be targeted by different antibodies, with common immunogen targets including amino acids 148-177, 111-220, and 24-208, depending on the antibody preparation .

What are the optimal applications and dilutions for WFDC1 antibodies?

WFDC1 antibodies have been validated for multiple applications with specific recommended dilutions:

It is recommended that each antibody be titrated in your specific testing system to obtain optimal results, as sample-dependent variations may occur .

How should I optimize antigen retrieval for WFDC1 immunohistochemistry?

For optimal WFDC1 detection in immunohistochemistry:

• Primary antigen retrieval recommendation: Use TE buffer pH 9.0

• Alternative method: Citrate buffer pH 6.0 can be used if TE buffer doesn't yield optimal results

• For paraffin-embedded tissues: Complete dewaxing is critical for antibody accessibility

• Incubation times: 30 minutes at room temperature for antibody binding is typically sufficient

• Signal development: Vector Blue substrate has been successfully used for visualization of WFDC1 in dual staining protocols

When developing protocols, it's important to note that different tissue types may require slight modifications to antigen retrieval methods. For example, in one study examining WFDC1 in diverse tissues, dual staining protocols were developed where chicken anti-ps20 antibody was visualized using Vector Blue substrate, while rabbit anti-CD31 antibody was visualized using NovaRED substrate .

What controls should be included when using WFDC1 antibodies for experimental validation?

Proper experimental controls are essential for validating WFDC1 antibody specificity:

For certain commercial antibodies, such as Prestige Antibodies, additional characterization has been performed, including testing against protein arrays of 364 human recombinant protein fragments and IHC tissue arrays of 44 normal human tissues and 20 common cancer type tissues .

How does WFDC1 modulate inflammatory and immune responses?

WFDC1 exhibits complex roles in immune regulation with context-dependent effects:

• Viral infection responses:

  • In influenza infection: Wfdc1-null mice exhibited 2.75-log-fold lower viral titer relative to control mice, suggesting enhanced viral resistance

  • In MHV (murine hepatitis virus) infection: Contrasting role observed where WFDC1 limited MHV-1 infectivity, as knockout mice showed increased lung viral titers

  • In HIV infection: Human WFDC1/ps20 promoted HIV infection in CD4 T cells by up-regulating intercellular adhesion molecule 1

• Inflammatory cell recruitment:

  • Neutrophil regulation: WFDC1 appears to regulate neutrophil-specific chemotactic factors and modulate neutrophil migration

  • Macrophage recruitment: Wfdc1-null infected lungs showed elevated macrophages and deposition of osteopontin, a potent macrophage chemokine

• Molecular mechanisms:

  • Osteopontin regulation: WFDC1 modulates core host response mechanisms partly via regulation of osteopontin and MMP-9 activity

  • Chemokine expression: Gene expression levels for neutrophil chemoattractants CXCL1 and CXCL2 are elevated in the lungs of ps20−/− mice post-MHV-1 infection

These findings collectively suggest that WFDC1 acts as a checkpoint regulator of emergency response mechanisms during normal adult tissue homeostasis, with its removal or downregulation being a key permissive event in coordinating inflammatory and repair processes .

What is the relationship between WFDC1 expression and cancer progression?

Research has revealed important connections between WFDC1 and cancer biology:

• Expression patterns in cancer:

  • Reduced expression: WFDC1/ps20 expression is diminished in reactive stroma in human prostate cancer, and this reduction is predictive of prostate cancer progression

  • Chromosomal location: WFDC1 is mapped to chromosome 16q24, a region frequently showing loss of heterozygosity in prostate, breast, and hepatocellular cancers

• Functional studies in cancer models:

  • Tumor suppression: Due to its location and growth inhibitory properties, WFDC1 has been suggested to function as a tumor suppressor gene

  • Paradoxical effects: Overexpression of WFDC1/ps20 in a recombined cancer/stromal cell mixed xenograft model resulted in elevated tumorigenesis attributable to increased angiogenesis

• Association with specific cancer types:

  • Prostate cancer: Multiple publications link WFDC1 with prostate diseases and cancer

  • Hepatocellular carcinoma: Literature reports associations between WFDC1 and liver cancer

  • Melanoma: Research indicates connections between WFDC1 and melanoma development

These findings suggest that WFDC1's role in cancer may be context-dependent, potentially serving as a tumor suppressor in some contexts while contributing to tumor progression in others, particularly through effects on the tumor microenvironment.

How does WFDC1 influence wound healing and tissue repair processes?

WFDC1 plays significant roles in wound healing and tissue repair:

• Wound closure dynamics:

  • Enhanced healing: Wfdc1-null mice exhibited an elevated rate of skin closure in wounding studies

  • Cellular mechanisms: This accelerated healing was associated with elevated deposition of osteopontin and macrophage recruitment

• Cellular behaviors in wound contexts:

  • Fibroblast function: Wfdc1-null fibroblasts showed impaired spheroid formation, elevated adhesion to fibronectin, and increased rates of wound closure in vitro

  • Reversible effects: These alterations were reversed by neutralizing antibody to osteopontin, highlighting a key molecular mediator

• Molecular pathways:

  • Osteopontin processing: Osteopontin mRNA and cleaved protein were up-regulated in Wfdc1-null cells treated with lipopolysaccharide or polyinosinic-polycytidylic acid

  • MMP-9 activity: WFDC1 absence was associated with constitutively active MMP-9, which cleaves osteopontin into its active form

The data suggest that WFDC1 normally functions as a brake on repair mechanisms, and its downregulation or absence permits accelerated wound healing responses through specific molecular pathways involving osteopontin and MMP-9.

How can I resolve discrepancies between predicted and observed molecular weights for WFDC1?

Researchers frequently observe differences between calculated and experimental molecular weights for WFDC1:

• Expected vs. observed weights:

  • Calculated molecular weight: 24 kDa (220 amino acids)

  • Commonly observed molecular weight: 29 kDa in Western blots

• Reasons for discrepancies:

  • Post-translational modifications: Glycosylation and other modifications can increase apparent molecular weight

  • Protein conformation: Structural features may affect migration in SDS-PAGE

  • Antibody specificity: Different antibodies may recognize specific isoforms or modified forms

• Methodological approaches:

  • Validate with multiple antibodies targeting different epitopes

  • Use recombinant WFDC1 as a size control

  • Employ knockout/knockdown controls to confirm band specificity

  • Consider deglycosylation treatments to assess contribution of glycosylation to apparent size

When analyzing Western blot results, focus on consistent patterns rather than absolute molecular weights, and always include appropriate positive and negative controls for accurate interpretation.

What strategies can resolve inconsistent WFDC1 staining in immunohistochemistry?

Inconsistent IHC results can be addressed through systematic optimization:

• Common challenges:

  • Variable staining intensity

  • High background

  • Weak or absent signal

  • Non-specific binding

• Optimization strategies:

  • Antigen retrieval: Compare TE buffer pH 9.0 with citrate buffer pH 6.0; adjust treatment time

  • Antibody titration: Test a range of dilutions (e.g., 1:20-1:200) to determine optimal concentration

  • Blocking optimization: Use species-appropriate serum or commercial blocking solutions

  • Detection system selection: Compare different visualization methods (e.g., DAB vs. fluorescent)

• Tissue-specific considerations:

  • Different fixation methods may affect epitope availability

  • Tissue type influences optimal protocols (e.g., breast cancer vs. small intestine tissue)

  • Consider testing multiple antibodies targeting different WFDC1 epitopes

Always include positive control tissues known to express WFDC1 (such as human breast cancer tissue or small intestine tissue) and negative controls to validate staining specificity .

How can I interpret conflicting data on WFDC1's role in different disease models?

Reconciling contradictory findings about WFDC1 function requires careful consideration:

• Context-dependent functions:

  • Viral infection responses: WFDC1 promotes HIV infection in CD4 T cells by up-regulating intercellular adhesion molecule 1, while limiting murine hepatitis virus infectivity

  • Cancer biology: Functions as a potential tumor suppressor in some contexts but may promote tumorigenesis through angiogenesis in others

• Analytical framework:

  • Consider cell/tissue type specificity: WFDC1 may have different effects in epithelial vs. stromal cells

  • Examine dose-dependency: Concentration levels may determine whether effects are stimulatory or inhibitory

  • Evaluate in vivo vs. in vitro differences: Results from cell culture may not always translate to complex tissue environments

  • Consider temporal factors: Acute vs. chronic effects may differ substantially

• Integrated interpretation approach:

  • Synthesize data across multiple model systems

  • Focus on molecular mechanisms rather than phenomenological outcomes

  • Consider WFDC1 as a context-dependent regulator rather than having a single defined function

  • Design experiments that directly test competing hypotheses in the same model system

The research suggests WFDC1 acts fundamentally as a homeostatic regulator whose function differs based on the specific biological context, explaining seemingly contradictory observations across different disease models .

What are promising approaches for studying WFDC1's role in age-related diseases?

Several research directions hold promise for understanding WFDC1 in age-related conditions:

• Degenerative disorders:

  • Macular degeneration: Mutations in WFDC1 have been associated with macular degeneration leading to blindness, though mechanisms remain unclear

  • Aging tissue homeostasis: Investigate how WFDC1 expression and function change across the lifespan

  • Fibrotic conditions: Explore connections between WFDC1, wound healing, and age-associated fibrosis

• Methodological approaches:

  • Conditional knockout models: Generate time-specific WFDC1 deletion to differentiate developmental from aging effects

  • Single-cell transcriptomics: Map WFDC1 expression changes in specific cell populations during aging

  • Spatial proteomics: Examine WFDC1 localization changes in aging tissues

• Therapeutic implications:

  • Anti-fibrotic interventions: Target WFDC1 pathways to modulate excessive scarring in aging tissues

  • Inflammatory regulation: Harness WFDC1's immunomodulatory effects to address inflammaging

  • Tissue regeneration: Manipulate WFDC1 levels to enhance repair in aged tissues

Researchers could particularly benefit from longitudinal studies of WFDC1 expression and function across the lifespan, potentially revealing age-specific roles in tissue homeostasis maintenance.

How might advanced imaging techniques enhance our understanding of WFDC1 biology?

Cutting-edge imaging approaches offer new insights into WFDC1 function:

• Advanced microscopy applications:

  • Super-resolution microscopy: Visualize WFDC1 subcellular localization beyond diffraction limits

  • Intravital imaging: Monitor WFDC1 dynamics in living tissues during inflammatory responses

  • Correlative light-electron microscopy: Connect WFDC1 localization to ultrastructural features

• Molecular imaging strategies:

  • FRET/BRET biosensors: Develop tools to monitor WFDC1 interactions with binding partners in real-time

  • Click chemistry approaches: Track newly synthesized WFDC1 during cellular responses

  • Multiplex imaging: Simultaneously visualize WFDC1 with multiple interaction partners or pathway components

• Translational imaging applications:

  • Patient-derived organoids: Image WFDC1 in 3D tissue models with disease-relevant mutations

  • Optical clearing techniques: Visualize WFDC1 distribution throughout intact organs

  • AI-assisted image analysis: Quantify subtle changes in WFDC1 expression patterns across large tissue datasets

These approaches could reveal previously undetected patterns of WFDC1 localization and activity, particularly during dynamic processes like inflammation and wound healing where temporal regulation is crucial.

What experimental approaches would best elucidate the relationship between WFDC1 and the extracellular matrix?

Understanding WFDC1-ECM interactions requires specialized methodological approaches:

• Biochemical and structural studies:

  • Protein interaction screening: Identify ECM binding partners of WFDC1 using techniques like BioID or proximity labeling

  • Structural biology: Determine crystal or cryo-EM structures of WFDC1-ECM protein complexes

  • Binding kinetics: Measure association/dissociation constants between WFDC1 and ECM components

• Functional assays:

  • 3D matrix culture systems: Compare cell behavior in ECM with and without WFDC1

  • Decellularized matrices: Study how WFDC1 incorporation affects ECM physical properties

  • Force microscopy: Measure how WFDC1 alters ECM mechanical properties and stiffness

• In vivo approaches:

  • Matrix-specific reporters: Generate transgenic models with fluorescent tags on both WFDC1 and key ECM components

  • Tissue-specific knockouts: Delete WFDC1 in specific cell types that contribute to ECM production

  • Inducible systems: Control WFDC1 expression temporally to examine dynamic ECM remodeling